Literature DB >> 582410

[Pharmacokinetics of triamterene and its active metabolites in renal insufficiency (author's transl)].

B Grebian, H E Geissler, H Knauf, E Mutschler, I Schnippenkoetter, K D Völger, U Wais.   

Abstract

1. After one oral dose of 100 mg triamterene plasma levels of triamterene (TA) and its metabolites hydroxytriamterene (OH-TA) and hydroxytriamterene sulfuric acid ester (OH-TA-ester) were studied in patients with normal and impaired renal function and in patients submitted to hemodialysis. Triamterene and its metabolites were also determined in the urine and the dialysate, respectively. 2. Hydroxytriamterene sulfuric acid ester (OH-TA-ester) representing a phase-II-metabolite of triamterene was found to yield plasma concentrations which were always higher than those of native TA. 3. In decreased renal function the elimination half-lives (t 1/2) of TA and OH-TA-ester were increased yielding elevated plasma levels of TA and its metabolites. The data of t 1/2 for TA and OH-TA-ester correlated with the creatinine clearance in an almost hyperbolic fashion. 4. Dialysance values of about 2 to 4 ml/min were determined for TA and OH-TA-ester.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 582410

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].

Authors:  E Mutschler; H J Gilfrich; H Knauf; W Möhrke; K D Völger
Journal:  Klin Wochenschr       Date:  1983-09-15

2.  Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.

Authors:  H J Gilfrich; G Kremer; W Möhrke; E Mutschler; K D Völger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Antifolate effect of triamterene on human leucocytes and on a human lymphoma cell line.

Authors:  A Schalhorn; W Siegert; H J Sauer
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Delayed elimination of triamterene and its active metabolite in chronic renal failure.

Authors:  H Knauf; W Möhrke; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.